A urine albumin-creatinine ratio (UACR) > 700 mg/g signifies severe kidney damage, and nephrology referral is recommended for intensified management. The impact of UACR ≥ 700 mg/g on outcomes and the efficacy of kidney protective therapies in patients have not been thoroughly examined. Using claims healthcare data from the USA, we identified prevalent patients with chronic kidney disease and a UACR measurement on 1 January 2022, and grouped them by UACR level. We also identified new users of sodium-glucose cotransporter 2 inhibitors (SGLT2i) between 2021 and 2023. Outcomes included estimated glomerular filtration rate (eGFR) slopes and risks of adverse outcomes and mortality. Of the 46,626 patients with UACR ≥ 300 mg/g, 23,998 had UACR ≥ 700 mg/g. In the UACR ≥ 700 and UACR 300 to < 700 mg/g groups, mean age was 72 and 74 years, median eGFR was 42 and 50 mL/min/1.73 m2, median UACR was 1376 and 437 mg/g at baseline and eGFR slopes were - 5.5 and - 3.1 mL/min/1.73 m2 per year, respectively. Compared to the UACR < 10 mg/g group, adjusted hazard ratio of risk of cardiorenal hospitalizations was 5.83 (95% CI 5.55-6.12) and 3.53 (95% CI 3.34-3.73), atherosclerotic cardiovascular disease hospitalizations was 2.97 (95% CI 2.76-3.19) and 2.33 (95% CI 2.15-2.52), and all-cause death was 2.89 (95% CI 2.78-3.02) and 2.10 (95% CI 2.01-2.20) in the UACR ≥ 700 and UACR 300 to < 700 mg/g groups, respectively. Of the 5908 new users of SGLT2i with UACR ≥ 700 mg/g, UACR and eGFR slope improved as expected (to 720 mg/g and - 2.44 mL/min/1.73 m2 per year, respectively). A UACR ≥ 700 mg/g identifies patients at high risk of accelerated kidney function decline and adverse outcomes. While emerging therapies such as SGLT2i had the expected benefits, the persistence of residual proteinuria/albuminuria and associated risks highlight an unmet need for optimized and new treatment strategies.
Pecoits–Filho et al. (2025) studied this question.